Nordic Bioscience Holding A/s

NORDIC BIOSCIENCE HOLDING A/S

DK

Investment brief

Investment brief: Nordic Bioscience Holding A/s

Create a free account to read 3 full briefs a month: verdict, strengths, risks, how you could invest and what the price implies. No card needed.

Founding members

The first 100 accounts get 3 months free

98 of 100 free places left · 2 taken

Create your account and get full access for 3 months — no card, no automatic charge. After that it is 20 € a month, only if you choose to continue.

Create a free account

Already have an account? Sign in

Key figures · FY2025

Revenue
DKK 426.29m
Growth
-19.2%
3-year growth (yearly)
—
Net income
DKK 54.53m
Gross margin
79.4%
Operating margin
—
Net margin
12.8%
Free cash flow
-DKK 68.59m
Cash
DKK 136.69m
Long-term debt
—
Net cash
—
Dividends + buybacks
DKK 220m

Four-year trend

Revenue
2024: DKK 527.39mDKK 527.39m20242025: DKK 426.29mDKK 426.29m2025
Net income
2024: DKK 170.81mDKK 170.81m20242025: DKK 54.53mDKK 54.53m2025
Operating cash flow
2024: DKK 379.86mDKK 379.86m20242025: -DKK 44.76m-DKK 44.76m2025

Annual figures from the company's ESEF annual report; the earlier year is that report's comparative. Operating margin is computed in code as operating income divided by revenue.

Place in every ranking

This company is not in the rankings (they cover companies with at least USD 1 bn in revenue).

Figures for FY2025 (period ending 2026-01-01) from the company's ESEF annual report (IFRS, consolidated), in DKK. Prior year comes from the same report's comparatives. A dash (—) means the figure was not tagged in a comparable form. These lists rank companies by reported figures. A high rank is a fact about the numbers, not a recommendation to buy, sell or hold, and not personalised advice. Past results do not predict future returns.

Find a company